Logo
I

Intercept Pharmaceuticals

357 employees

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

Investor insights

Funding rounds participated in

$448M sweet spot round size

Investor type

Public Company

Basic info

Industry

Pharmaceutical Manufacturing

Sectors

Pharmaceutical Manufacturing

Date founded

2002

Funding rounds raised

Total raised

$448M

from investors over 1 rounds

I

Intercept Pharmaceuticals raised $448M on July 30, 2016

FAQ